Curated News: Top Hit Stories

Filters close
Released: 16-Sep-2024 9:05 AM EDT
Xylyx Bio awarded $2.45M NIH SBIR grant from NIDDK to facilitate development of effective drugs for fibrotic liver disease
Xylyx Bio, Inc.

Award supports the development of a cell-based assay platform to help scientists discover and test drug candidates for liver fibrosis.

   
Released: 16-Sep-2024 8:00 AM EDT
Rare Gene Variants Raise Risk of Developing ALS and Lead to More Rapid Progression
American Neurological Association (ANA)

People with rare genetic variants associated with Parkinson’s disease and other neurodegenerative disorders are at increased risk of developing amyotrophic lateral sclerosis (ALS), according to new research presented at the 149th Annual Meeting of the American Neurological Association (ANA). The study is the first to find that rare variants linked to other neurodegenerative diseases are associated with ALS, also known as Lou Gehrig’s disease. Researchers also found having these rare variants raises the risk of faster progression of ALS as well as shorter survival.

Newswise: How do I know if I have a Cold, the Flu or COVID?
Released: 16-Sep-2024 8:00 AM EDT
How do I know if I have a Cold, the Flu or COVID?
Hackensack Meridian Health

While colds and flu are detected year round in the U.S., the prevalence of both tends to increase in the fall and winter. Add in COVID-19, and you’ll see a lot of overlap. A Hackensack Meridian Health expert shares what you need to know to be ready for the season.

Released: 16-Sep-2024 8:00 AM EDT
MS Patients with Chronic Brain Lesions Decline Faster
American Neurological Association (ANA)

Starting patients with multiple sclerosis (MS) on aggressive treatment earlier may help prevent the development of paramagnetic rim lesions (PRL), areas of chronic brain inflammation that are linked to faster decline due to the disease, suggests new research presented at the 149th Annual Meeting of the American Neurological Association (ANA). People with MS who have PRLs tend to have greater brain atrophy and disability. Treatment for MS includes low-, moderate- or high-efficacy disease-modifying therapies (DMTs), such as monoclonal antibodies, immunomodulators and immunosuppressants. While high-efficacy DMTs have more side effects, previous research suggests they may help prevent PRLs from forming (unlike low- or moderate-efficacy DMTs), potentially outweighing the downsides. No currently available DMT has been shown to reduce existing PRLs.

11-Sep-2024 9:10 AM EDT
1 in 5 parents worry their elementary and middle school aged kids don’t have friends
Michigan Medicine - University of Michigan

Over half of parents report at least one factor that makes it difficult for their child to make new friends, with about one in five saying that shyness or being socially awkward got in the way of their child’s efforts to make new friends.

13-Sep-2024 12:05 PM EDT
Researchers Discover New Blood Group System – MAL
University of Bristol

The discovery of a new blood group, MAL, has solved a 50- year-old mystery. The findings allow identification and treatment of rare patients lacking this blood group.

Released: 15-Sep-2024 6:25 PM EDT
Getting Autism Right
Rutgers University-New Brunswick

Contrary to common perceptions and years of research that autistic people can’t describe their emotions or often have muted emotional responses, a Rutgers study published in the American Journal of Occupational Therapy concludes that many autistic adults are in fact acutely aware of their feelings and can label them in vivid, often colorful detail.

Newswise: sabygeorgenewweb.jpg
Released: 15-Sep-2024 11:05 AM EDT
Roswell Park-Designed Treatment Regimen Doubles Progression-Free Survival in Metastatic Kidney Cancer
Roswell Park Comprehensive Cancer Center

During the European Society for Medical Oncology (ESMO) Congress, Saby George, MD, FACP, of Roswell Park Comprehensive Cancer Center presented findings on a novel two-agent treatment that more than doubled progression-free survival compared with single-agent treatment.

Released: 15-Sep-2024 8:05 AM EDT
Artificial Intelligence Poised to Transform Neurological Care from Diagnosis to Treatment, Even Prevention
American Neurological Association (ANA)

Artificial intelligence (AI) is poised to revolutionize the care of neurological diseases, from detecting tumors the human eye can’t see and using implantable devices to manage various conditions to crunching data from thousands of people with the same condition to guide the development of new treatments, according to neurologists and biomedical researchers speaking at the Presidential Symposium – Present and Future Applications of AI in Neurological Care and Research at the 149th Annual Meeting of the American Neurological Association (ANA).

Released: 15-Sep-2024 8:00 AM EDT
Vaping Bad for Brain Health, First-of-its Kind Study Shows
American Neurological Association (ANA)

College students who vaped had lower cognitive function scores than those who didn’t, and the more they vaped, the bigger the disparity, according to first-of-its-kind research being presented at the 149th Annual Meeting of the American Neurological Association (ANA). The study also found college students who vaped and smoked had the lowest scores. While using electronic cigarettes (vaping) has been shown to cause lung damage, the research presented at ANA is groundbreaking because there is little to no information on vaping’s relationship to cognitive function, such as learning, memory, problem-solving, critical thinking and decision-making. Cognitive testing is rarely performed in young people.

13-Sep-2024 9:45 AM EDT
ESMO: Combination Therapy Reduced Agitated Delirium in Patients with Advanced Cancers
University of Texas MD Anderson Cancer Center

Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common end-of-life condition for patients with advanced cancers, compared with haloperidol alone, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center.

Newswise: Mike-Wiest_Jess-Lopes_Emeline-Gaunce_Derin_Timucin_summer2024_2024-09-03-190934_iuif.jpg?w=924.55657492355&h=617&q=90&auto=format&fit=crop&dm=1725390575&s=1e91dfa662f219fa4dc935c2edf232e4
Released: 13-Sep-2024 4:05 PM EDT
Wellesley Team’s New Research on Anesthesia Unlocks Important Clues About the Nature of Consciousness
Wellesley College

Wellesley team’s new research on anesthesia unlocks important clues about the nature of consciousness

Newswise: STScI-01J6CWRK073C5KH4QHGP1Z6KA2.png?w=980&h=654&q=90&auto=format&fit=crop&dm=1725560642&s=4ce4d46b6fb5003d9e347c2c65ed6c18
Released: 13-Sep-2024 4:05 PM EDT
A Cosmic Question Mark?
Wellesley College

A cosmic question mark?

Newswise: Albert Einstein College of Medicine Receives Major Federal Grant to Help Lead National Effort for Pandemic Preparedness
Released: 13-Sep-2024 3:30 PM EDT
Albert Einstein College of Medicine Receives Major Federal Grant to Help Lead National Effort for Pandemic Preparedness
Albert Einstein College of Medicine

Albert Einstein College of Medicine has received a five-year, $14 million per year grant from the National Institute of Allergy and Infectious Diseases (NIAID) to participate in a broad national effort to develop "plug-and-play" vaccines and antibody-based therapies against a wide range of emerging viruses. The grant is part of NIAID’s new Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network, which was announced earlier today.

Newswise: WCS Scientist Awarded Prestigious U.S. National Science Foundation Fellowship to Investigate Deforestation and Wildlife Viruses
Released: 13-Sep-2024 2:05 PM EDT
WCS Scientist Awarded Prestigious U.S. National Science Foundation Fellowship to Investigate Deforestation and Wildlife Viruses
Wildlife Conservation Society

Dr. Charles C.Y. Xu has joined the Wildlife Conservation Society (WCS) Health Program as a postdoctoral scientist funded by a prestigious 3-year fellowship from the U.S. National Science Foundation (NSF).

Newswise: Lying in Wait: MOF Are Traps for Toxic Gases
Released: 13-Sep-2024 2:05 PM EDT
Lying in Wait: MOF Are Traps for Toxic Gases
Department of Energy, Office of Science

Metal organic frameworks (MOFs) show promise as a way to trap toxic molecules and mitigate their harmful effects. In this research, scientists studied how the structure of MOFs can be tuned to enhance and optimize trapping of nitrogen dioxide and sulfur dioxide.

Released: 13-Sep-2024 1:05 PM EDT
CDPH Releases Official Guidance on Use of CRNAs in Anesthesia Care
American Society of Anesthesiologists (ASA)

The California Department of Public Health (CDPH) released new guidance for general acute care hospitals providing a “Reminder of Certified Registered Nurse Anesthetist Requirements.” The All Facilities Letter (AFL) clarifies the credentialing and privileging requirements for nurse anesthetists (CRNAs), and outlines the state and federal laws and regulations that form the foundation for these requirements and guide the scope of practice for CRNAs.

Released: 13-Sep-2024 12:05 PM EDT
Emergency Department Screening Identifies Suicide Risk in Nearly 80% of Transgender and Gender Diverse Youth
Ann and Robert H. Lurie Children's Hospital of Chicago

Transgender and gender diverse (TGD) youth are more than five times more likely to screen positive for suicide risk compared to cisgender females, who tend to screen positive at higher rates than cisgender males, according to a study from Ann & Robert H. Lurie Children’s Hospital of Chicago published in the journal Academic Pediatrics.

Newswise: Giving Batteries a Longer Life with the Advanced Photon Source
Released: 13-Sep-2024 12:05 PM EDT
Giving Batteries a Longer Life with the Advanced Photon Source
Argonne National Laboratory

Argonne contributes to landmark research that could lead to better cathodes for longer-lasting lithium-ion batteries.

Released: 13-Sep-2024 12:00 PM EDT
Expert Available: Boeing Workers Reject Company’s Proposal and Vote to Strike
George Washington University

Roughly 96% of union members voted Thursday to reject a proposed deal with the company that would have significantly boosted pay and benefits, but fell short of other union demands. ...



close
3.12394